Request a demo specialized to your need.
When a director asks what the company has actually spent across its active trials this quarter not what was budgeted, what was spent the finance lead at a growing biotech often has to say "let me pull that together" instead of just answering. Not because the number doesn't exist. Because it exists in six places: a budget tracker for Trial A, an invoice folder for Trial B, an email thread with the CRO running Trial C, and a spreadsheet somebody built in 2024 to hold it all together.
That gap has real consequences. A trial that's quietly running over budget doesn't get flagged until the quarterly reconciliation, by which point the option to course-correct is gone. A board that doesn't trust the numbers starts asking finance to double-check everything, which slows every future request. And the person who has to stand up and explain a variance nobody saw coming carries that professionally, even when the root cause was a reporting gap, not a spending decision.
Why This Gap Opens Up at the Mid-Size Stage Specifically
The mid-size stage is where it breaks down: several trials running in parallel, each through a different CRO, each CRO reporting spend on its own schedule and in its own format, and a finance team of two or three people expected to consolidate all of it into one coherent picture on demand.
Protocol amendments make this worse. Industry analysis from the Tufts Center for the Study of Drug Development has found that pivotal trials commonly go through more than two protocol amendments before completion, and each one changes visit schedules, site costs, and monitoring plans which means the budget a finance team is reconciling against is rarely the budget that was originally approved. Without a system that connects protocol change to budget impact automatically, that reconciliation work falls entirely on whoever is holding the spreadsheet.
What "Portfolio Financial Visibility" Actually Means
Portfolio financial visibility is the ability to see budget-versus-actual spend, accruals, and payment status across every active trial and every CRO relationship in one place, in real time rather than reconstructing that picture study by study whenever someone asks for it. It's the difference between having the data somewhere and being able to answer a question with it in the time it takes to ask.
For a mid-size biotech, that means one system showing:
- Spend and forecast by trial, by CRO, and by therapeutic area or program
- Accruals that update as visits and milestones complete, not just at month-end close
- Site and vendor payment status without emailing a CRO to ask
- Variance flags the moment a trial drifts from its approved budget, not at the next scheduled reconciliation
Spreadsheet Consolidation vs. Single-Study Tools vs. Cloudbyz CTFM
| Spreadsheet Consolidation | Single-Study Budget Tools | Cloudbyz CTFM | |
|---|---|---|---|
| View across multiple trials/CROs | Manual, rebuilt each time | Not designed for it one study at a time | Native, real-time, portfolio-level |
| Time to answer "what's our burn?" | Days, depending on who's available | Hours per study, then manual rollup | Minutes |
| Protocol amendment impact on budget | Tracked manually, if at all | Limited | Flagged and modeled automatically |
| Audit trail across trials | Fragmented across files and emails | Exists per study, not consolidated | Single, timestamped, 21 CFR Part 11-ready trail |
| Multi-currency / multi-CRO reporting | Manual conversion, error-prone | Depends on tool | Built in, consistent across the portfolio |
| Dependency on one person's spreadsheet | High | Moderate | None |
6 Questions Worth Asking Before Meeting
- Can I state total clinical spend across all active trials right now, without emailing anyone?
- Do I know which trial, if any, is trending over its approved budget and by how much?
- If a protocol amendment happened last month, do I know its dollar impact yet?
- Can I show, with a timestamp, when each site payment was approved and made?
- If a trial underperforms, can I see how quickly budget could be reallocated to one that's accelerating?
- Is any of this dependent on a spreadsheet that lives on one laptop?
If more than one or two of these gets a "not really," the gap isn't a people problem it's a systems one.
How Cloudbyz CTFM Closes the Gap
Cloudbyz CTFM is built natively on Salesforce, which means it doesn't sit beside your clinical operations data it shares the same platform as Cloudbyz CTMS, eTMF, and EDC. Budgets, accruals, payments, and forecasts for every trial and every CRO relationship live in one system, with portfolio-level dashboards that roll up spend by program, phase, geography, or CRO partner without a manual rebuild.
Two capabilities matter most for a lean finance team specifically:
- CTFM Financial Navigator is a read-only conversational agent inside CTFM. Ask it a plain-English question what's our current spend on Trial B versus budget" and get an answer in seconds instead of a 10-to-15-minute lookup, without changing a single record.
- Invoice Processing & Reconciliation automatically matches site and vendor invoices against the system proforma, classifies line items, flags variances, and routes only genuine exceptions for human approval so a two-person finance team isn't manually reconciling every invoice from every CRO by hand.
Together, they turn portfolio financial visibility from a monthly assembly project into something that's simply already there when someone asks.
Book a demo with Cloudbyz team to understand better for its capabilities.
Subscribe to our Newsletter
